$13.61
+2.4%Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
No Dividend Yield Data
AMLX has not reported any dividend yield values in the available annual periods.
No Dividend Payout Ratio Data
AMLX has not reported any dividend payout ratio values in the available annual periods.
No Net Dividends Paid Data
AMLX has not reported any net dividends paid values in the available annual periods.
Total Payments
3
Latest Dividend
$0.4200
Annual Amount
$1.0200
Frequency
Quarterly
| Declaration | Ex-Date | Payment Date | Dividend | Adjusted | Frequency | Growth |
|---|---|---|---|---|---|---|
Jan 25, 2018 | Mar 28, 2018 | Apr 2, 2018 | $0.4200 | $0.4200 | Quarterly | +16.67% |
N/A | Dec 28, 2017 | Jan 2, 2018 | $0.3600 | $0.3600 | Quarterly | +50.00% |
N/A | Sep 28, 2017 | Oct 2, 2017 | $0.2400 | $0.2400 | Quarterly | - |
Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.
Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.
Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.
Continue your AMLX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.